PUBLISHER: The Business Research Company | PRODUCT CODE: 1760639
PUBLISHER: The Business Research Company | PRODUCT CODE: 1760639
Mycobacterium tuberculosis is a slow-growing, rod-shaped bacterium that primarily targets the lungs, although it can also affect other body parts. It is the pathogen responsible for tuberculosis (TB), a contagious disease transmitted through airborne droplets when an infected person coughs, sneezes, or speaks. The bacterium has a distinct, waxy cell wall made of mycolic acid, which provides resistance to drying and helps it persist in the environment.
The primary product types associated with Mycobacterium tuberculosis include instruments, reagents and consumables, and software solutions. Instruments refer to the medical devices and equipment used for diagnosing and researching TB. Diagnosis can be achieved through various techniques, such as culture-based methods, molecular testing, and immunological assays, with administration routes being either oral or injectable. These products are used by various end users, including hospitals, diagnostic labs, and research institutions.
The mycobacterium tuberculosis market research report is one of a series of new reports from The Business Research Company that provides mycobacterium tuberculosis market statistics, including mycobacterium tuberculosis industry global market size, regional shares, competitors with a mycobacterium tuberculosis market share, detailed mycobacterium tuberculosis market segments, market trends and opportunities, and any further data you may need to thrive in the mycobacterium tuberculosis industry. This mycobacterium tuberculosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The mycobacterium tuberculosis market size has grown strongly in recent years. It will grow from $3.54 billion in 2024 to $3.74 billion in 2025 at a compound annual growth rate (CAGR) of 5.5%. The growth during the historic period can be attributed to the rising number of TB cases in high-burden countries, increased funding from international organizations, the expansion of TB screening programs, a higher incidence of TB-HIV co-infections, and the growth in global travel and migration, which have contributed to the spread of TB.
The mycobacterium tuberculosis market size is expected to see strong growth in the next few years. It will grow to $4.57 billion in 2029 at a compound annual growth rate (CAGR) of 5.2%. The growth during the forecast period is expected to be driven by the increasing prevalence of TB worldwide, the rising global incidence of drug-resistant TB, heightened awareness about TB transmission and prevention, government initiatives and funding for TB elimination, and increased research and development efforts focused on TB treatment. Key trends in the forecast period include advances in TB diagnostic technologies, the availability of rapid TB testing methods, the introduction of new TB vaccines, the development of new drug regimens for multidrug-resistant TB, and technological innovations in TB drug formulation.
The growth of the mycobacterium tuberculosis market is expected to be driven by increased investments in research and development. Research and development (R&D) involves the creation of new knowledge or the improvement of existing products, services, or technologies through systematic investigation and experimentation. The rising investment in R&D is fueled by rapid technological advancements, creating the need for constant innovation to remain competitive in the global market. R&D contributes to mycobacterium tuberculosis treatment by discovering novel drug candidates capable of overcoming resistance to current therapies, thus enhancing treatment efficacy and patient outcomes. For example, in March 2024, the UK government announced a $5 million (£4 million) funding boost for the TB REACH program, aimed at supporting innovative strategies for improving tuberculosis diagnosis and treatment in low- and middle-income countries. This initiative will provide healthcare to 500,000 people, help detect TB in 37,000 individuals, and potentially save more than 15,000 lives. As a result, the increased investment in R&D is set to drive the growth of the mycobacterium tuberculosis market.
Companies in the mycobacterium tuberculosis market are focusing on developing advanced solutions such as automated tuberculosis tests to provide faster, more accurate diagnoses. Automated tuberculosis tests are diagnostic tools that use automated systems and advanced technologies to rapidly and accurately detect Mycobacterium tuberculosis and drug resistance, with minimal human intervention. For instance, in April 2025, Revvity Inc., a US-based biotechnology company, announced that the U.S. Food and Drug Administration (FDA) approved the Auto-Pure 2400 liquid handling platform with the T-SPOT TB test. The integration of the Auto-Pure 2400 platform with the T-SPOT.TB test improves automated tuberculosis testing by enabling higher-volume processing while maintaining accuracy. This platform combines liquid handling and magnetic cell isolation technologies, testing up to 24 samples per run, completing Day 1 of testing in under 3.5 hours, and requiring minimal user involvement. The T-SPOT.TB test, recognized by the WHO as the only ELISPOT-based IGRA, ensures reproducible results with fewer indeterminate outcomes, reduces the need for repeat testing, and provides reliable performance for immunocompromised patients.
In November 2023, Becton Dickinson and Company (BD), a US-based provider of tuberculosis diagnostics, collaborated with Bio Farma to help Indonesia eliminate the spread of tuberculosis. This partnership aims to enhance access to BD's innovative TB diagnostics portfolio and improve the TB solutions supply chain in Indonesia. It also offers Bio Farma the opportunity to deepen its expertise in the development of diagnostic kits. Bio Farma is an Indonesia-based manufacturer of tuberculosis vaccines.
Major players in the mycobacterium tuberculosis market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Novartis AG, Becton Dickinson and Company, Viatris Inc., Macleods Pharmaceuticals Limited, bioMerieux SA, Bio-Rad Laboratories Inc., Bruker Corporation, QIAGEN N.V., Lupin Limited, Zydus Cadila Healthcare Limited, Cepheid Inc., Serum Institute of India Pvt. Ltd., Oxford Immunotec USA Inc., Panacea Biotec Limited, International AIDS Vaccine Initiative Inc., HiMedia Laboratories Private Limited, and Akonni Biosystems Inc.
North America was the largest region in the mycobacterium tuberculosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in mycobacterium tuberculosis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the mycobacterium tuberculosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The mycobacterium tuberculosis market consists of revenues earned by entities by providing services such as tuberculosis strain typing and genotyping services, contract research services, biorepository services, and genomic sequencing services. The market value includes the value of related goods sold by the service provider or included within the service offering. The mycobacterium tuberculosis market also includes sales of diagnostic kits, antibodies, antigens, recombinant proteins, nucleic acid extraction kits, and biosafety equipment. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Mycobacterium Tuberculosis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on mycobacterium tuberculosis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for mycobacterium tuberculosis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The mycobacterium tuberculosis market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.